for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oncternal Therapeutics Inc

ONCT.OQ

Latest Trade

1.55USD

Change

0.00(0.00%)

Volume

5,156

Today's Range

1.55

 - 

1.61

52 Week Range

1.50

 - 

6.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.55
Open
1.57
Volume
5,156
3M AVG Volume
1.85
Today's High
1.61
Today's Low
1.55
52 Week High
6.25
52 Week Low
1.50
Shares Out (MIL)
19.92
Market Cap (MIL)
30.87
Forward P/E
--
Dividend (Yield %)
--

Next Event

Oncternal Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Oncternal Therapeutics Announces Presentation Of Interim Phase 1 Clinical Trial Data For TK216

Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering

Oncternal Posts Q2 Loss Per Share Of $0.34

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.

Industry

Biotechnology & Drugs

Contact Info

12230 El Camino Real Ste 300

SAN DIEGO, CA

92130-2090

United States

+1.858.4341113

http://www.oncternal.com/

Executive Leadership

David F. Hale

Independent Chairman of the board

James B. Breitmeyer

President, Chief Executive Officer, Director

Richard G. Vincent

Chief Financial Officer, Treasurer, Secretary

Gunnar F. Kaufmann

Chief Scientific Officer

Igor P. Bilinsky

Chief Business Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.750

2018

-1.650

2019

-3.310

2020(E)

-1.190
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.44
Price To Book (MRQ)
2.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.14
LT Debt To Equity (MRQ)
3.14
Return on Investment (TTM)
-117.24
Return on Equity (TTM)
-77.59

Latest News

Latest News

BRIEF-Oncternal Therapeutics Announces Orphan Drug Designations Of Cirmtuzumab Antibody For Treatment Of Mantle Cell Lymphoma And Chronic Lymphocytic Leukemia

* ONCTERNAL THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATIONS OF CIRMTUZUMAB ROR1 ANTIBODY FOR TREATMENT OF MANTLE CELL LYMPHOMA AND FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA Source text for Eikon: Further company coverage:

BRIEF-Oncternal Therapeutics Announces Increased Focus Of Antibody Program On Mantle Cell Lymphoma

* ONCTERNAL THERAPEUTICS ANNOUNCES INCREASED FOCUS OF THE CIRMTUZUMAB ROR1 ANTIBODY PROGRAM ON MANTLE CELL LYMPHOMA

Oncternal wins dismissal of shareholder lawsuit over GTx merger

Biotechnology company Oncternal Therapeutics, which specializes in cancer treatments, has won dismissal of a lawsuit by shareholders who said they were shortchanged by the company's merger with GTx Inc.

BRIEF-Armistice Capital Reports 9.1% Passive Stake In Oncternal Therapeutics

* ARMISTICE CAPITAL REPORTS 9.1% PASSIVE STAKE IN ONCTERNAL THERAPEUTICS INC, AS OF MAY 19, 2020

BRIEF-Oncternal Therapeutics Announced Updated Interim Clinical Data From The Ongoing Phase 1/2 Cirll Clinical Trial

* ONCTERNAL THERAPEUTICS- ANNOUNCED UPDATED INTERIM CLINICAL DATA FROM THE ONGOING PHASE 1/2 CIRLL CLINICAL TRIAL Source text: [https://bit.ly/3e0rXC6] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Oncternal Provides Announces Q1 2020 Financial Results

* ONCTERNAL PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Oncternal Discloses Additional Interim Data From Open-Label, First-In-Human, Multicenter Phase 1 Clinical Trial Evaluating Tk216

* ONCTERNAL THERAPEUTICS IC - DISCLOSED ADDITIONAL INTERIM DATA FROM OPEN-LABEL, FIRST-IN-HUMAN, MULTICENTER PHASE 1 CLINICAL TRIAL EVALUATING TK216

BRIEF-Oncternal Announces Q4 2019 Financial Results

* ONCTERNAL PROVIDES BUSINESS UPDATE AND ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Oncternal Therapeutics Announces Interim Clinical Data Update

* ONCTERNAL THERAPEUTICS ANNOUNCES INTERIM CLINICAL DATA UPDATE, INCLUDING 50% COMPLETE RESPONSE RATE, FOR CIRMTUZUMAB IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH MANTLE CELL LYMPHOMA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up